{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T06:09:42Z","timestamp":1790143782783,"version":"4.0.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2009,11,12]],"date-time":"2009-11-12T00:00:00Z","timestamp":1257984000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2010,6]]},"DOI":"10.1007\/s00432-009-0720-3","type":"journal-article","created":{"date-parts":[[2009,11,11]],"date-time":"2009-11-11T09:35:09Z","timestamp":1257932109000},"page":"803-809","source":"Crossref","is-referenced-by-count":24,"title":["The value of XPD and XRCC1 genotype polymorphisms to predict clinical outcome in metastatic colorectal carcinoma patients with irinotecan-based regimens"],"prefix":"10.1007","volume":"136","author":[{"given":"Mehmet","family":"Artac","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hakan","family":"Bozcuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sacide","family":"Pehlivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song\u00fcl","family":"Akcan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa","family":"Pehlivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tugce","family":"Sever","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa","family":"Ozdogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Burhan","family":"Savas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,11,12]]},"reference":[{"key":"720_CR1","first-page":"6921","volume":"60","author":"Y Ando","year":"2000","unstructured":"Ando Y, Saka H, Ando M et al (2000) Polymorphisms of UDP glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res 60:6921\u20136926","journal-title":"Cancer Res"},{"key":"720_CR2","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/sj.bjc.6604134","volume":"98","author":"D Balin-Gauthier","year":"2008","unstructured":"Balin-Gauthier D, Delord J-P, Pillaire M-J et al (2008) Cetuximab potentiates oxaliplatin cytotoxic effect through a defect in NER and DNA replication initiation. Br J Cancer 98:120\u2013128","journal-title":"Br J Cancer"},{"key":"720_CR3","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1200\/JCO.2007.15.5580","volume":"26","author":"MS Braun","year":"2008","unstructured":"Braun MS, Richman SD, Quirke P et al (2008) Predictive biomarkers of chemotherapy efficacy in colorectal cancer: results from UK MRC FOCUS Trial. J Clin Oncol 26:2690\u20132698","journal-title":"J Clin Oncol"},{"key":"720_CR4","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1158\/1078-0432.1226.11.3","volume":"11","author":"LE Carlini","year":"2005","unstructured":"Carlini LE, Meropol NJ, Bever J et al (2005) UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine\/irinotecan. Clin Cancer Res 11:1226\u20131236","journal-title":"Clin Cancer Res"},{"key":"720_CR5","doi-asserted-by":"crossref","first-page":"5526","DOI":"10.1093\/nar\/gkg761","volume":"31","author":"SF El-Khamisy","year":"2003","unstructured":"El-Khamisy SF, Masutani M, Suzuki H, Caldecott KW (2003) A requirement for PARP-1 for the assembly or stability of XRCC1 nuclear foci at sites of oxidative DNA damage. Nucleic Acids Res 31:5526\u20135533","journal-title":"Nucleic Acids Res"},{"key":"720_CR6","volume-title":"GLOBOCAN 2002: cancer incidence, mortality and prevalence worldwide. IARC Cancer Base no. 5, version 2.0","author":"J Ferlay","year":"2004","unstructured":"Ferlay J, Bray F, Pisani P, Parkin DM (2004) GLOBOCAN 2002: cancer incidence, mortality and prevalence worldwide. IARC Cancer Base no. 5, version 2.0. IARC Press, Lyon"},{"key":"720_CR7","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1200\/JCO.2004.08.067","volume":"22","author":"S Gurubhagavatula","year":"2004","unstructured":"Gurubhagavatula S, Liu G, Park S et al (2004) XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy. J Clin Oncol 22:2594\u20132601","journal-title":"J Clin Oncol"},{"issue":"1\u20132","key":"720_CR8","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.mrfmmm.2007.02.002","volume":"619","author":"RD Hansen","year":"2007","unstructured":"Hansen RD, Sorensen M, Tj\u00f8nneland A et al (2007) XPA A23G, XPC Lys939Gln, XPD Lys751Gln and XPD Asp312Asn polymorphisms, interactions with smoking, alcohol and dietary factors, and risk of colorectal cancer. Mutat Res 619(1\u20132):68\u201380","journal-title":"Mutat Res"},{"issue":"1","key":"720_CR9","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/cr.2008.7","volume":"18","author":"JK Horton","year":"2008","unstructured":"Horton JK, Watson M, Stefanick DF, Shaughnessy DT, Taylor JA, Wilson SH (2008) XRCC1 and DNA polymerase beta in cellular protection against cytotoxic DNA single-strand breaks. Cell Res 18(1):48\u201363","journal-title":"Cell Res"},{"issue":"6","key":"720_CR10","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1158\/1078-0432.CCR-07-1472","volume":"14","author":"JM Hoskins","year":"2008","unstructured":"Hoskins JM, Marcuello E, Altes A et al (2008) Irinotecan pharmacogenetics: influence of pharmacodynamic genes. Clin Cancer Res 14(6):1788\u20131796","journal-title":"Clin Cancer Res"},{"issue":"Suppl","key":"720_CR11","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1007\/s002800051077","volume":"42","author":"L Iyer","year":"1998","unstructured":"Iyer L, Ratain MJ (1998) Clinical pharmacology of camptothecins. Cancer Chemother Pharmacol 42(Suppl):S31\u2013S43","journal-title":"Cancer Chemother Pharmacol"},{"issue":"Suppl 4","key":"720_CR12","doi-asserted-by":"crossref","first-page":"iv173","DOI":"10.1093\/annonc\/mdh923","volume":"15","author":"HJ Lenz","year":"2004","unstructured":"Lenz HJ (2004) Pharmacogenomics and colorectal cancer. Ann Oncol 15(Suppl 4):iv173\u2013iv177","journal-title":"Ann Oncol"},{"issue":"9","key":"720_CR13","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/j.ejca.2008.03.025","volume":"44","author":"E Martinez-Balibrea","year":"2008","unstructured":"Martinez-Balibrea E, Abad A, Aranda E et al (2008) Pharmacogenetic approach for capecitabine or 5-fluorouracil selection to be combined with oxaliplatin as first-line chemotherapy in advanced colorectal cancer. Eur J Cancer 44(9):1229\u20131237","journal-title":"Eur J Cancer"},{"key":"720_CR14","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1056\/NEJMra040958","volume":"352","author":"JA Meyerhardt","year":"2005","unstructured":"Meyerhardt JA, Mayer RJ (2005) Systemic therapy for colorectal cancer. N Engl J Med 352:476\u2013487","journal-title":"N Engl J Med"},{"issue":"5\u20136","key":"720_CR15","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1159\/000113534","volume":"72","author":"M Monzo","year":"2007","unstructured":"Monzo M, Moreno I, Navarro A et al (2007) Single nucleotide polymorphisms in nucleotide excision repair genes XPA, XPD, XPG and ERCC1 in advanced colorectal cancer patients treated with first line oxaliplatin\/fluoropyrimidine. Oncology 72(5\u20136):364\u2013370","journal-title":"Oncology"},{"issue":"24","key":"720_CR16","first-page":"8654","volume":"61","author":"DJ Park","year":"2001","unstructured":"Park DJ, Stoehlmacher J, Zhang W, Tsao-Wei DD, Groshen S, Lenz HJ (2001) A xeroderma pigmentosum group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer. Cancer Res 61(24):8654\u20138658","journal-title":"Cancer Res"},{"issue":"2","key":"720_CR17","first-page":"459","volume":"62","author":"SY Park","year":"2002","unstructured":"Park SY, Lam W, Cheng YC (2002) X-ray repair cross-complementing gene I protein plays an important role in camptothecin resistance. Cancer Res 62(2):459\u2013465","journal-title":"Cancer Res"},{"issue":"3","key":"720_CR18","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1124\/jpet.104.081265","volume":"313","author":"SK Quinney","year":"2005","unstructured":"Quinney SK, Sanghani SP, Davis WI et al (2005) Hydrolysis of capecitabine to 5\u2032-deoxy-5-5-fluorocytidine by human carboxylesterases and inhibition by loperamide. J Pharmacol Exp Ther 313(3):1011\u20131016","journal-title":"J Pharmacol Exp Ther"},{"issue":"7","key":"720_CR19","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1093\/annonc\/mdi227","volume":"16","author":"DW Rea","year":"2005","unstructured":"Rea DW, Nortier JWR, Ten Bokkel Huinink WW et al (2005) A phase I\/II and pharmacokinetic study of irinotecan in combination with capecitabine as first-line therapy for advanced colorectal cancer. Ann Oncol 16(7):1123\u20131132","journal-title":"Ann Oncol"},{"key":"720_CR20","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1038\/sj.tpj.6500463","volume":"8","author":"A Ruzzo","year":"2008","unstructured":"Ruzzo A, Graziano F, Loupakis F et al (2008) Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFIRI chemotherapy. Pharmacogenomics J 8:278\u2013288","journal-title":"Pharmacogenomics J"},{"key":"720_CR21","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1056\/NEJM200009283431302","volume":"343","author":"LB Saltz","year":"2000","unstructured":"Saltz LB, Cox JV, Blanke C et al (2000) Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 343:905\u2013914","journal-title":"N Engl J Med"},{"key":"720_CR22","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1002\/jso.20196","volume":"89","author":"S Stelzner","year":"2005","unstructured":"Stelzner S, Hellmich G, Koch R, Ludwig K (2005) Factors predicting survival in stage for colorectal carcinoma patients after palliative treatment: a multivariate analysis. J Surg Oncol 89:211\u2013217","journal-title":"J Surg Oncol"},{"key":"720_CR23","first-page":"3075","volume":"21","author":"J Stoehlmacher","year":"2001","unstructured":"Stoehlmacher J, Ghaderi V, Iobal S et al (2001) A polymorphism of the XRCC1 gene predicts for response to platinum based treatment in advanced colorectal cancer. Anticancer Res 21:3075\u20133079","journal-title":"Anticancer Res"},{"issue":"2","key":"720_CR24","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1038\/sj.bjc.6601975","volume":"91","author":"J Stoehlmacher","year":"2004","unstructured":"Stoehlmacher J, Park DJ, Zhang W et al (2004) A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU\/oxaliplatin combination chemotherapy in refractory colorectal cancer. Br J Cancer 91(2):344\u2013354","journal-title":"Br J Cancer"},{"key":"720_CR25","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1245\/s10434-006-9112-y","volume":"13","author":"KW Suh","year":"2006","unstructured":"Suh KW, Kim JH, Kim DY, Kim YB, Lee C, Choi S (2006) Which gene is a dominant predictor of response during FOLFOX chemotherapy for the treatment of metastatic colorectal cancer, the MTHFR or XRCC1 gene? Ann Surg Oncol 13:1379\u20131385","journal-title":"Ann Surg Oncol"},{"key":"720_CR26","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1038\/365852a0","volume":"365","author":"P Sung","year":"1993","unstructured":"Sung P, Bailly V, Weber C, Thompson LH, Prakash L, Prakash L (1993) Human xeroderma pigmentosum group D gene encodes a DNA helicase. Nature (Lond) 365:852\u2013855","journal-title":"Nature (Lond)"},{"key":"720_CR27","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1128\/MCB.22.8.2556-2563.2002","volume":"22","author":"RM Taylor","year":"2002","unstructured":"Taylor RM, Thistlethwaite A, Caldecott KW (2002) Central role for the XRCC1 BRCT I domain in mammalian DNA single-strand break repair. Mol Cell Biol 22:2556\u20132563","journal-title":"Mol Cell Biol"},{"key":"720_CR28","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.exer.2007.06.003","volume":"85","author":"M \u00dcnal","year":"2007","unstructured":"\u00dcnal M, G\u00fcven M, Batar B, \u00d6zayd\u0131n A, Sarici A, Devranoglu K (2007) Polymorphisms of DNA repair genes XPD and XRCC1 and risk of cataract development. Exp Eye Res 85:328\u2013334","journal-title":"Exp Eye Res"},{"key":"720_CR29","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1002\/ijc.22129","volume":"119","author":"D Vallb\u00f6hmer","year":"2006","unstructured":"Vallb\u00f6hmer D, Iqbal S, Yang DY et al (2006) Molecular determinants of irinotecan efficacy. Int J Cancer 119:2435\u20132442","journal-title":"Int J Cancer"},{"key":"720_CR30","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1124\/mol.61.4.742","volume":"61","author":"J Wu","year":"2002","unstructured":"Wu J, Yin MB, Hapke G, Toth K, Rustum YM (2002) Induction of biphasic DNA double strand breaks and activation of multiple repair protein complexes by DNA topoisomerase I drug 7-ethyl-10-hydroxy-camptothecin. Mol Pharmacol 61:742\u2013748","journal-title":"Mol Pharmacol"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-009-0720-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00432-009-0720-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-009-0720-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,27]],"date-time":"2023-05-27T13:59:37Z","timestamp":1685195977000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00432-009-0720-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,11,12]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010,6]]}},"alternative-id":["720"],"URL":"https:\/\/doi.org\/10.1007\/s00432-009-0720-3","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,11,12]]}}}